Background: We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients.
Methods: Data were pooled from 1059 patients in six trials. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were compared by log-rank test between patients aged < 70 (n=857; 81%) and ≥70 (n=202; 19%) years.
Results: In first-line patients, median PFS was comparable in younger and older patients, 9.9 vs 11.0 months, respectively (HR, 0.89; 95% CI: 0.73-1.09; P=0.2629), as was median OS, 23.6 vs 25.6 months (HR, 0.93; 95% CI: 0.74-1.18; P=0.5442). Similarly, in cytokine-refractory patients, median PFS was 8.1 vs 8.4 months (HR, 0.79; 95% CI: 0.49-1.28; P=0.3350), while median OS was 20.2 vs 15.8 months (HR, 1.14; 95% CI: 0.73-1.79; P=0.5657). Some treatment-emergent adverse events were significantly less common in younger vs older patients, including fatigue (60% vs 69%), cough (20% vs 29%), peripheral edema (17% vs 27%), anemia (18% vs 25%), decreased appetite (13% vs 29%), and thrombocytopenia (16% vs 25%; all P< 0.05). Hand-foot syndrome was more common in younger patients (32% vs 24%).
Conclusions: Advanced age should not be a deterrent to sunitinib therapy and elderly patients may achieve additional clinical benefit.
Written by:
Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, Martell B, Matczak E, Motzer RJ. Are you the author?
Baylor Sammons Cancer Center-Texas Oncology, PA, Dallas, TX, USA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; Royal Marsden Hospital NHS Trust, London, UK; 4Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; PUCRS School of Medicine, Porto Alegre, Brazil; Institut Gustave Roussy, Villejuif, France; Pfizer Oncology, La Jolla, CA, USA; Pfizer Oncology, Groton, CT, USA; Pfizer Oncology, New York, NY, USA; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Reference: Br J Cancer. 2014 Mar 4;110(5):1125-32.
doi: 10.1038/bjc.2013.832
PubMed Abstract
PMID: 24434434
UroToday.com Renal Cancer Section
